Publications

The Lancet. Oncology

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

01-07-2019

Nature cell biology

Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.

01-06-2019

PloS one

Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.

28-05-2019

JCI insight

Frequent clonal relations between metastases and non-index prostate cancer lesions.

24-01-2019

Nature communications

Integrative epigenetic taxonomy of primary prostate cancer.

21-11-2018

Nature medicine

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

01-11-2018

BMC bioinformatics

XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data.

04-10-2018

Molecular systems biology

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.

05-03-2018

Cancer cell

Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.

12-02-2018

Nature medicine

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

01-02-2018

Cancer research

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

01-11-2017

Nature

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.

12-10-2017

Genome research

Massive reshaping of genome-nuclear lamina interactions during oncogene-induced senescence.

01-10-2017

BMC cancer

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.

15-09-2017

EMBO molecular medicine

Phenotypic diversity drives paracrine drug tolerance.

01-08-2017

FASEB journal : official publication of the Federation of American Societies for Experimental Biology

Fatty acid 16:4(n-3) stimulates a GPR120-induced signaling cascade in splenic macrophages to promote chemotherapy resistance.

01-05-2017

Nature reviews. Cancer

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

01-04-2017

Oncotarget

Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer.

15-03-2017

Oncotarget

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.

12-07-2016

Cell reports

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.

28-06-2016

Oncotarget

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.

07-06-2016

Oncotarget

Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts disease-free survival.

22-12-2015

Carcinogenesis

Autophagy-mediated degradation of nuclear envelope proteins during oncogene-induced senescence.

01-11-2015

Proceedings of the National Academy of Sciences of the United States of America

Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases.

27-10-2015

Journal of proteome research

PhosphoPath: Visualization of Phosphosite-centric Dynamics in Temporal Molecular Networks.

02-10-2015

EMBO molecular medicine

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.

01-09-2015

Molecular oncology

Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.

01-08-2015

Journal of proteome research

Signal Transduction Reaction Monitoring Deciphers Site-Specific PI3K-mTOR/MAPK Pathway Dynamics in Oncogene-Induced Senescence.

02-07-2015

Cell cycle (Georgetown, Tex.)

Two-way communication between the metabolic and cell cycle machineries: the molecular basis.

04-06-2015

Pigment cell & melanoma research

Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.

01-05-2015

Genome biology

CopywriteR: DNA copy number detection from off-target sequence data.

27-02-2015

Molecular systems biology

ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma.

23-12-2014

Nature communications

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

15-12-2014

Cell reports

Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition.

20-11-2014

Cancer research

Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy.

01-11-2014

Molecular oncology

Cancer drug resistance: old concept, novel solutions required.

12-09-2014

Molecular & cellular proteomics : MCP

Phosphoproteome dynamics in onset and maintenance of oncogene-induced senescence.

01-08-2014

Pigment cell & melanoma research

Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence identifies RASEF, a gene epigenetically silenced in melanoma.

01-07-2014

Nature

A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence.

06-06-2013

Proceedings of the National Academy of Sciences of the United States of America

Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis.

26-03-2013

Genes & development

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.

15-05-2012

Pigment cell & melanoma research

Oncogene-induced senescence and melanoma: where do we stand?

01-12-2011

The EMBO journal

C/EBPβ: lost beyond translation.

14-09-2011

Oncogene

Zeb1 is required for TrkB-induced epithelial-mesenchymal transition, anoikis resistance and metastasis.

01-09-2011

The EMBO journal

Antagonistic TSC22D1 variants control BRAF(E600)-induced senescence.

04-05-2011

PloS one

Functional characterization of human cancer-derived TRKB mutations.

17-02-2011

Genes & development

The essence of senescence.

15-11-2010

Aging

Epithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths.

01-10-2010

Cancer cell

PICS-ure this: prosenescence therapy?

16-03-2010

Carcinogenesis

Functional identification of LRF as an oncogene that bypasses RASV12-induced senescence via upregulation of CYCLIN E.

01-02-2010

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.

Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.

Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.

Frequent clonal relations between metastases and non-index prostate cancer lesions.

Integrative epigenetic taxonomy of primary prostate cancer.

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.

XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data.

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.

Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.

Massive reshaping of genome-nuclear lamina interactions during oncogene-induced senescence.

Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study.

Phenotypic diversity drives paracrine drug tolerance.

Fatty acid 16:4(n-3) stimulates a GPR120-induced signaling cascade in splenic macrophages to promote chemotherapy resistance.

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer.

Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation.

Fra-1 is a key driver of colon cancer metastasis and a Fra-1 classifier predicts disease-free survival.

Autophagy-mediated degradation of nuclear envelope proteins during oncogene-induced senescence.

Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases.

PhosphoPath: Visualization of Phosphosite-centric Dynamics in Temporal Molecular Networks.

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.

Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.

Signal Transduction Reaction Monitoring Deciphers Site-Specific PI3K-mTOR/MAPK Pathway Dynamics in Oncogene-Induced Senescence.

Two-way communication between the metabolic and cell cycle machineries: the molecular basis.

Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.

CopywriteR: DNA copy number detection from off-target sequence data.

ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma.

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition.

Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy.

Cancer drug resistance: old concept, novel solutions required.

Phosphoproteome dynamics in onset and maintenance of oncogene-induced senescence.

Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence identifies RASEF, a gene epigenetically silenced in melanoma.

A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence.

Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis.

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.

Oncogene-induced senescence and melanoma: where do we stand?

C/EBPβ: lost beyond translation.

Zeb1 is required for TrkB-induced epithelial-mesenchymal transition, anoikis resistance and metastasis.

Antagonistic TSC22D1 variants control BRAF(E600)-induced senescence.

Functional characterization of human cancer-derived TRKB mutations.

The essence of senescence.

Epithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths.

PICS-ure this: prosenescence therapy?

Functional identification of LRF as an oncogene that bypasses RASV12-induced senescence via upregulation of CYCLIN E.

This site uses cookies